Life-science briefing: Wednesday, March 19, 2008
TODAY’S HEADLINES:
Paris-based Stentys takes $18M for “bifurcated” stents (release)
Blood analyzer IntelliDx raises $22M (PDF release)
Cancer-test biotech Calderome changes name to VeraCyte (VentureWire)
Predictive Biosciences names Peter Klemm as CEO (release)
Paris-based Stentys takes $18M for “bifurcated” stents – Stentys, a Paris-based medical device maker, raised $18 million in a second funding round. The company is developing “bifurcated” stents intended to prop open clogged arteries at blood-vessel junctions.
The startup said the funding will allow it to complete clinical trials… Continue Reading
Dune Networks takes $12M for ethernet switching platforms
A Sunnyvale, Calif. company that manufactures networking devices used in data centers and carrier’s ethernet switching platforms, Dune Networks was founded in 2000 and began selling its products four years later.
The company is its own fabless semiconductor supplier, but also has partnerships with companies including Altera, Intel and Lattice Semiconductor. It is currently making a profit, thought it has not disclosed the numbers.
The $12 million investment was led by US Venture Partners. Existing investors Alta… Continue Reading